Clinical Use of the Interferon Inducer IIBI in Patients with Refractory Hodgkin’s Lymphoma

Clinical Use of the Interferon Inducer IIBI in Patients with Refractory Hodgkin’s Lymphoma

This study evaluated the effects of the immunobiological preparation "Interferon inducer bacterial liquid" (IIBI) combined with chemoradiotherapy (CRT) in patients with refractory Hodgkin’s lymphoma (HL) are presented. The clinical application of IIBI increases the efficacy of treatment. I...

Full description

Bibliographic Details
Main Authors: Daniar R. Aspetov, Maria N. Omarova, Lyazzat Zh. Orakbay, Raiymkul K. Karakulov, Kairat S. Doskhozhayev, Bayan Kh. Zhumatova, Meruyert D. Chazhayeva
Format: Article
Language:English
Published: International Medical Research and Development Corporation 2015-12-01
Series:International Journal of Biomedicine
Subjects:
Hodgkin’s lymphoma;
chemoradiotherapy;
immunotherapy;
INF inducer;
Online Access:http://ijbm.org/articles/Article5(4)_OA9.pdf
Description
Summary:This study evaluated the effects of the immunobiological preparation "Interferon inducer bacterial liquid" (IIBI) combined with chemoradiotherapy (CRT) in patients with refractory Hodgkin’s lymphoma (HL) are presented. The clinical application of IIBI increases the efficacy of treatment. IIBI in combination with CRT induces the production of highly active endogenous IFN-α/β, provides a marked regression of the affected lymph nodes in a short period (within 7 to 10 days) of treatment, relieves B symptoms, and increases by 2 times the length of remission in patients with refractory HL.
ISSN:2158-0510
2158-0529

Similar Items